好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

SNT-MC17/Idebenone for the Treatment of Patients with Friedreich's Ataxia: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Efficacy and Safety
Muscle Disease/Neuromuscular Junction
(-)
120
Authors/Disclosures
David R. Lynch, MD, PhD (Children's Hospital of Philadelphia) The institution of Dr. Lynch has received research support from reata. The institution of Dr. Lynch has received research support from PTC. Dr. Lynch has received intellectual property interests from a discovery or technology relating to health care.
Susan L. Perlman, MD (UCLA) Dr. Perlman has nothing to disclose.
No disclosure on file
Pierre Vankan (Santhera Pharmaceuticals) No disclosure on file
Thomas Meier, PhD (Santhera Pharmaceuticals) No disclosure on file
Gretchen L. Birbeck, MD, MPH, DTMH, FAAN (University of Rochester/CHET) An immediate family member of Dr. Birbeck has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Various. Dr. Birbeck has a non-compensated relationship as a Ambassador for Zambia with RSTMH that is relevant to AAN interests or activities.